Drug Discovery and Development, Volume 1 (eBook)
476 Seiten
John Wiley & Sons (Verlag)
978-0-471-78009-0 (ISBN)
Modern drug discovery and development require the collaborative efforts of specialists in a broadarray of scientific, technical, and business disciplines--from biochemistry to molecular biology, organic chemistry to medicinal chemistry, pharmacology to marketing. Yet surprisingly, until now, there were no authoritative references offering a complete, fully integrated picture of the process.
The only comprehensive guide of its kind, this groundbreaking two-volume resource provides an overview of the entire sequence of operations involved in drug discovery and development--from initial conceptualization to commercialization to clinicians and medical practitioners. Volume 1: Drug Discovery describes all the steps in the discovery process, including conceptualizing a drug, creating a library of candidates for testing, screening candidates for in vitro and in vivo activity, conducting and analyzing the results of clinical trials, and modifying a drug as necessary. Volume 2: Drug Development delves into the nitty-gritty details of optimizing the synthetic route, drug manufacturing, outsourcing, and marketing--including drug coloring and delivery methods.
Featuring contributions from a world-class team of experts, Drug Discovery and Development:
* Features fascinating case studies, including the discovery and development of erythromycin analogs, Tagamet, and Ultiva (remifentanil)
* Discusses the discovery of medications for bacterial infections, Parkinson's disease, psoriasis, peptic ulcers, atopic dermatitis, asthma, and cancer
* Includes chapters on combinatorial chemistry, molecular biology-based drug discovery, genomics, and chemogenomics
Drug Discovery and Development is an indispensable working resource for industrialchemists, biologists, biochemists, and executives who work in the pharmaceutical industry.
Mukund S. Chorghade, PHD, is President of Chorghade Enterprises, Inc., a firm based in Natick, Massachusetts that provides consultations to major pharmaceutical companieson collaborations with worldwide academic, government, and industrial laboratories; European technology-based companies; process reengineering; and project management of technology transfer.
Contributors.
Preface.
1. From Patent to Prescription: Paving the Perilous Path to Profit (Richard J. Pariza).
2. Medicinal Chemistry in the New Millennium: A Glance into the Future (Paul W. Erhardt).
ADMET-Related Synergies, 59
3. Contemporary Drug Discovery (Lester A. Mitscher and Apurba Dutta).
4. Combinatorial Chemistry in the Drug Discovery Process (Ian Hughes).
5. Parallel Solution-Phase Synthesis (Norton P. Peet and Hwa-Ok Kim).
6. Timing of Analog Research in Medicinal Chemistry (Janos Fischer and Aniko Gere).
7. Possible Alternatives to High-Throughput Screening (Camille G. Wermuth).
8. Proteomics and Drug Discovery (Susan Dana Jones and Peter G. Warren).
Appendix: Public-Domain Software Tools and Databases.
9. Using Drug Metabolism Databases During Drug Design and Development (Paul W. Erhardt).
10. Discovery of the Antiulcer Drug Tagamet (C. Robin Ganellin).
11. Discovery of Potent Nonpeptide Vasopressin Receptor Antagonists (Bruce E. Maryanoff).
12. Discovery and Development of the Ultrashort-Acting Analgesic Remifentanil (Paul L. Feldman).
13. Discovery and Development of Nevirapine (Karl Grozinger, John Proudfoot, and Karl Hargrave).
14. Applications of Nuclear Imaging in Drug Discovery and Development (John W. Babich and William C. Eckelman).
15. Polymeric Sequestrants as Nonabsorbed Human Therapeutics (Pradeep K. Dhal, Chad C. Huval, and S. Randall Holmes-Farley).
16. Botanical Immunomodulators and Chemoprotectants in Cancer Therapy (Bhushan Patwardhan, Sham Diwanay, and Manish Gautam).
Index.
"...provides a nice survey of most of the key topics facing
discovery houses today." (Doody's Health Services)
"This reasonably priced book is well-written and produced. It
has a useful 32-page index, and it may be considered for
acquisition by individuals and libraries." (Journal of
Medicinial Chemistry, October 5, 2006)
| Erscheint lt. Verlag | 24.7.2006 |
|---|---|
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Laboratoriumsmedizin |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Naturwissenschaften ► Chemie | |
| Technik | |
| Schlagworte | Arzneimittelforschung • Chemie • Chemistry • Drug Discovery & Development • Medical Science • Medizin • Pharmaceutical & Medicinal Chemistry • Pharmacology & Pharmaceutical Medicine • Pharmakologie u. Pharmazeutische Medizin • Pharmazeutische Chemie • Pharmazeutische u. Medizinische Chemie • Wirkstoffforschung u. -entwicklung |
| ISBN-10 | 0-471-78009-X / 047178009X |
| ISBN-13 | 978-0-471-78009-0 / 9780471780090 |
| Haben Sie eine Frage zum Produkt? |
PDF (Adobe DRM)Größe: 6,0 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
